Nomogram predicting adverse pathology outcome on radical prostatectomy in low-risk prostate cancer men.
By: Jordan Nasri, Flora Barthe, Sneha Parekh, Parita Ratnani, Adriana M Pedraza, Vinayak G Wagaskar, Jonathan Olivier, Arnauld Villers, Ash Tewari

Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA; Univ. Lille, Department of Urology, Claude Huriez Hospital, CHU LILLE, F-59000 Lille, France. Electronic address: nasri.jordan@orange.fr.
2021-12-15; doi: 10.1016/j.urology.2022.02.019
Abstract

Objective

To develop and validate a prediction model to predict the risk of adverse pathology outcome on final pathology in low-risk PCa men.

Materials

This study was a monocentric retrospective analysis of 426 men who underwent RP for low-risk PCa. The validation cohort included 103 men from another hospital. Adverse pathology outcome was defined either by upgrading on RP GS (from GS 3+3 to GS ≥ 3+4 with Gleason pattern 4 ≥ 10%) or a non-organ confined disease (pathologic stage ≥ pT3a). Multivariable logistic regression analysis was performed to build nomogram for predicting adverse pathology outcome. Nomogram validation was performed by calculating the area under receiver operating characteristic curves (AUC) and comparing nomogram-predicted probabilities with actual rates of adverse pathology outcome in the external cohort. The Kaplan-Meier method was used to estimate and compare the BCR-free survival rates between the two groups.

Results

Of 426 men in the development cohort, 45.7% showed adverse pathology outcome on RP. Age, BMI, PSAD, history of prior negative biopsy, MRI PIRADS score 4-5 and number of positive biopsies were significant predictors in multivariate analysis. A nomogram was constructed with an area under curve of 87%. There was agreement between predicted and actual rates of adverse pathology outcome in the validation cohort. The 5-year BCR-free survival rates in patients with and without adverse pathology outcome was 70% and 98%, respectively.

Conclusion

This novel nomogram would help identify low-risk PCa men at risk of adverse pathology outcome and can be relevant for treatment decision-making.



Copyright © 2022. Published by Elsevier Inc.

PMID:35263642






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements